Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

Overview of attention for article published in Frontiers in immunology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Readers on

mendeley: 16 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 52,081 followers.

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab https://t.co/0CdnxjJ7sM #algoritmetx #feedly

23 Nov 2022

Reply Repost Favourite

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab https://t.co/Vi2hR093dz

21 Nov 2022

Reply Repost Favourite

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab https://t.co/u0bKnLpBRn https://t.co/F0csUCb2th

04 Nov 2022

Reply Repost Favourite

New Research: Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab: Purpose Immune-mediated adverse events (imAEs) may be associated with… https://t.co/L

04 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.